These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8858303)

  • 1. Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed.
    Berdeu D; Puech R; Loubatières-Mariani MM; Bertrand G
    Eur J Pharmacol; 1996 Jul; 308(3):301-4. PubMed ID: 8858303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat.
    Berdeu D; Gross R; Puech R; Loubatières-Mariani MM; Bertrand G
    Eur J Pharmacol; 1995 Feb; 275(1):91-8. PubMed ID: 7774667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevation of cytosolic calcium by imidazolines in mouse islets of Langerhans: implications for stimulus-response coupling of insulin release.
    Shepherd RM; Hashmi MN; Kane C; Squires PE; Dunne MJ
    Br J Pharmacol; 1996 Nov; 119(5):911-6. PubMed ID: 8922740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080.
    Brown CA; Chan SL; Stillings MR; Smith SA; Morgan NG
    Br J Pharmacol; 1993 Nov; 110(3):1017-22. PubMed ID: 7905338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the imidazoline binding site involved in regulation of insulin secretion.
    Morgan NG; Chan SL; Brown CA; Tsoli E
    Ann N Y Acad Sci; 1995 Jul; 763():361-73. PubMed ID: 7677348
    [No Abstract]   [Full Text] [Related]  

  • 6. Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion.
    Mourtada M; Brown CA; Smith SA; Piercy V; Chan SL; Morgan NG
    Br J Pharmacol; 1997 Jun; 121(4):799-805. PubMed ID: 9208151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the putative endogenous imidazoline receptor ligand, clonidine-displacing substance, on insulin secretion from rat and human islets of Langerhans.
    Chan SL; Atlas D; James RF; Morgan NG
    Br J Pharmacol; 1997 Mar; 120(5):926-32. PubMed ID: 9138700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonidine-displacing substance and its putative role in control of insulin secretion: a minireview.
    Chan SL
    Gen Pharmacol; 1998 Oct; 31(4):525-9. PubMed ID: 9792210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites.
    Brown CA; Loweth AC; Smith SA; Morgan NG
    Br J Pharmacol; 1993 Feb; 108(2):312-7. PubMed ID: 8095415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The imidazoline I1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of Langerhans.
    Tsoli E; Chan SL; Morgan NG
    Eur J Pharmacol; 1995 Sep; 284(1-2):199-203. PubMed ID: 8549627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin secretagogues with an imidazoline structure inhibit arginine-induced secretion from isolated glucagon secretion from isolated rat islets of Langerhans.
    Mourtada M; Smith SA; Morgan NG
    Biochem Biophys Res Commun; 1997 Jul; 236(1):162-6. PubMed ID: 9223445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sigma receptor ligands and imidazoline secretagogues mediate their insulin secretory effects by activating distinct receptor systems in isolated islets.
    Chan SL; Morgan NG
    Eur J Pharmacol; 1998 Jun; 350(2-3):267-72. PubMed ID: 9696417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with sigma receptors.
    Chan SL; Pallett AL; Clews J; Ramsden CA; Morgan NG
    Eur J Pharmacol; 1997 Apr; 323(2-3):241-4. PubMed ID: 9128845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan.
    Chan SL; Mourtada M; Morgan NG
    Diabetes; 2001 Feb; 50(2):340-7. PubMed ID: 11272145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels.
    Chan SL; Morgan NG
    Eur J Pharmacol; 1990 Jan; 176(1):97-101. PubMed ID: 2178947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clotrimazole and efaroxan stimulate insulin secretion by different mechanisms in rat pancreatic islets.
    Chan SL; Pallett AL; Morgan NG
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Dec; 356(6):763-8. PubMed ID: 9453462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites.
    Chan SL; Brown CA; Scarpello KE; Morgan NG
    Br J Pharmacol; 1994 Aug; 112(4):1065-70. PubMed ID: 7952865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of imidazoline binding site ligands on the growth and viability of clonal pancreatic beta-cells.
    Mourtada M; Elliott J; Smith SA; Morgan NG
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Feb; 361(2):146-54. PubMed ID: 10685869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade by agmatine of catecholamine release from chromaffin cells is unrelated to imidazoline receptors.
    Santos WC; Hernández-Guijo JM; Ruiz-Nuño A; Olivares R; Jurkiewicz A; Gandía L; García AG
    Eur J Pharmacol; 2001 Apr; 417(1-2):99-109. PubMed ID: 11301064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple effector pathways regulate the insulin secretory response to the imidazoline RX871024 in isolated rat pancreatic islets.
    Mourtada M; Chan SL; Smith SA; Morgan NG
    Br J Pharmacol; 1999 Jul; 127(5):1279-87. PubMed ID: 10455276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.